Design Therapeutics, Inc. (DSGN): Insider Trading, Congress Trades & Research | Tormere

DSGN

$10.22+5.69%visit website

Design Therapeutics, Inc.

Market Cap

$654M

Live price × SEC shares (Oct 30, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

1.70

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Sep 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

3.2

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	Q3 FY2026 Sep 30, 2026	TTM Sep 30, 2026
Revenue	0.00	0.00	0.00	0.00	0.00
Research & development	13,425	14,379	16,388	16,926	61,118
Total operating expenses	18,169	19,706	22,177	22,230	82,282
Operating income	(18,169)	(19,706)	(22,177)	(22,230)	(82,282)
Net income	(15,997)	(17,636)	(20,165)	(20,288)	(74,086)
EPS (basic) ($)		(0.29)	(0.32)	(0.32)	(1.20)
EPS (diluted) ($)		(0.29)	(0.32)	(0.32)	(1.20)
Weighted avg. shares (basic)		61,434	62,505	63,036
Weighted avg. shares (diluted)		61,434	62,505	63,036

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Nov 4, 2026, period ended Sep 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 23 more quarters, back to Mar 2020, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

No Form 4 transactions on record.

Recent News

Design Therapeutics (DSGN) Stock Price, Chart & Analysis

www.debelegger.nl · 2026-11-06

$66.3M sold so far; Design Therapeutics (DSGN) may sell more common stock.

Stock Titan · 2026-11-04

With $208.6M in cash and investments, Design Therapeutics (DSGN) posts a wider Q3 loss.

Stock Titan · 2026-11-04

Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates

Yahoo · 2026-11-04

Data from a genetic-disease drug trial are expected after 12 weeks of treatment in early 2027

Stock Titan · 2026-11-04

Design Therapeutics Authorizes Up To $200M In Common Stock Sales Through Jefferies

Benzinga · 2026-11-04

Design Therapeutics Files Prospectus For Offering $300M Mixed Shelf

Benzinga · 2026-11-04

Design Therapeutics Q3 EPS $(0.32) Beats $(0.35) Estimate

Benzinga · 2026-11-04

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Simply Wall St · 2026-10-13

Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027

Seeking Alpha · 2026-10-04

Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference

Yahoo Finance · 2026-05-28

Design Therapeutics Shares Jump on Encouraging Friedreich Ataxia Trial Results (DSGN)

Yahoo Finance · 2026-05-18

Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia

Yahoo Finance · 2026-05-18

This Biotech Leader Ran Up As Much As 18% — And Then Lost It All

Investor's Business Daily · 2026-05-18

Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026

Yahoo Finance · 2026-05-17

Informational purposes only, not investment advice.